
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics is a promising clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases, with a strong emphasis on the function of regulatory T cells. The recent publication of a peer-reviewed study showcasing the elevated biomarkers for ALS strengthens the company's rationale and framework for its approach, while also differentiating it from other late-stage ALS therapies. Additionally, the company's FY2025 financial results demonstrate a healthy balance sheet and promising clinical updates, positioning it for potential success in its lead asset, COYA 302.
Bears say
Coya Therapeutics is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases, but has yet to provide registrational evidence to support its pipeline. While their most recent publication in Brain Communications reinforces the biologic rationale for one of their programs, it does not have a significant impact on financial estimates. However, the release does provide external validation to their platform and helps to de-risk their scientific foundation for future development.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares